SEARCH

SEARCH BY CITATION

References

  • 1
    UNAIDS. Report on the Global AIDS Epidemic. Geneva, Switzerland, UNAIDS, 2006, Available at: http://www.unaids.org/en/HIVdata/2006GlobalReport/default.asp, accessed on 16 November 2007.
  • 2
    Ngugi EN, Chakkalackal M, Sharma A, Bukusi E, Njoroge B, Kimani J, MacDonald KS, Bwayo JJ, Cohen CR, Moses S, Kaul R: Sustained changes in sexual behavior by female sex workers after completion of a randomized HIV prevention trial. J Acquir Immune Defic Syndr 2007; 45:588–594.
  • 3
    Galvin SR, Cohen MS: The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33.
  • 4
    Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, VanCott T, Quinn TC: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149.
  • 5
    Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A: Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
  • 6
    Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO: Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643.
  • 7
    Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ: Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657.
  • 8
    UNAIDS. New Data on Male Circumcision and HIV Prevention. Geneva, Switzerland, Policy and Programme Implications, 2007. Available at: http://www.unaids.org/en/Policies/HIVPrevention/circumcisionUNAIDSpolicies.asp, accessed on 16 November 2007.
  • 9
    Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, Chaviano A, Bailey RC: Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002; 161:867.
  • 10
    Lederman MM, Offord RE, Hartley O: Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006; 6:371.
  • 11
    Koulinska IN, Villamor E, Chaplin B, Msamanga G, Fawzi W, Renjifo B, Essex M: Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr 2006; 41:93.
  • 12
    Dulioust E, Tachet A, De Almeida M, Finkielsztejn L, Rivalland S, Salmon D, Sicard D, Rouzioux C, Jouannet P: Detection of HIV-1 in seminal plasma and seminal cells of HIV-1 seropositive men. J Reprod Immunol 1998; 41:27.
  • 13
    Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, Zupancic M, Busch M, Carlis J, Wolinsky S, Haase AT: Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79:9217.
  • 14
    Quayle AJ: The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells. J Reprod Immunol 2002; 57:61.
  • 15
    Geijtenbeek TB, Torensma R, Van Vliet SJ, Van Duijnhoven GC, Adema GJ, Van Kooyk Y, Figdor CG: Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100:575.
  • 16
    Jameson B, Baribaud F, Pohlmann S, Ghavimi D, Mortari F, Doms RW, Iwasaki A: Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol 2002; 76:1866.
  • 17
    Sugaya M, Lore K, Koup RA, Douek DC, Blauvelt A: HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters. J Immunol 2004; 172:2219.
  • 18
    Gupta P, Collins KB, Ratner D, Watkins S, Naus GJ, Landers DV, Patterson BK: Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol 2002; 76:9868.
  • 19
    Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257.
  • 20
    Bomsel M: Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3:42.
  • 21
    Dezzutti CS, Guenthner PC, Cummins JE, Jr, Cabrera T, Marshall JH, Dillberger A, Lal RB: Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis 2001; 183:1204.
  • 22
    Asin SN, Wildt-Perinic D, Mason SI, Howell AL, Wira CR, Fanger MW: Human immunodeficiency virus type 1 infection of human uterine epithelial cells: viral shedding and cell contact-mediated infectivity. J Infect Dis 2003; 187:1522.
  • 23
    Klebanoff SJ, Coombs RW: Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med 1991; 174:289.
  • 24
    McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96:456.
  • 25
    Shugars DC: Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis 1999; 179(Suppl. 3):S431.
  • 26
    Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM: Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004; 200:1337.
  • 27
    Harmsen MC, Swart PJ, De Bethune MP, Pauwels R, De Clercq E, The TH, Meijer DK: Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995; 172:380.
  • 28
    Viani RM, Gutteberg TJ, Lathey JL, Spector SA: Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. AIDS 1999; 13:1273.
  • 29
    Moriuchi M, Moriuchi H: A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J Immunol 2001; 166:4231.
  • 30
    Saidi H, Eslahpazir J, Carbonneil C, Carthagena L, Requena M, Nassreddine N, Belec L: Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J Immunol 2006; 177:5540.
  • 31
    Groot F, Geijtenbeek TB, Sanders RW, Baldwin CE, Sanchez-Hernandez M, Floris R, Van Kooyk Y, De Jong EC, Berkhout B: Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J Virol 2005; 79:3009.
  • 32
    Lee-Huang S, Huang PL, Sun Y, Huang PL, Kung HF, Blithe DL, Chen HC: Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Proc Natl Acad Sci USA 1999; 96:2678.
  • 33
    Moutsopoulos NM, Greenwell-Wild T, Wahl SM: Differential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res 2006; 19:52.
  • 34
    Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, Medvik K, Sieg SF, Weinberg A: Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17:F39.
  • 35
    Feng Z, Dubyak GR, Lederman MM, Weinberg A: Cutting edge: human beta defensin 3--a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 2006; 177:782.
  • 36
    Weinberg A, Quinones-Mateu ME, Lederman MM: Role of human beta-defensins in HIV infection. Adv Dent Res 2006; 19:42.
  • 37
    Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298:1025.
  • 38
    Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM: Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005; 175:7560.
  • 39
    Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ: Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79:12164.
  • 40
    Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu Rev Biochem 1998; 67:227.
  • 41
    Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H: Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006; 80:7645.
  • 42
    Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF: Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4:1009.
  • 43
    Garcia-Sastre A, Biron CA: Type 1 interferons and the virus-host relationship: a lesson in detente. Science 2006; 312:879.
  • 44
    Littman DR: Chemokine receptors: keys to AIDS pathogenesis? Cell 1998; 93:677.
  • 45
    Agace WW, Amara A, Roberts AI, Pablos JL, Thelen S, Uguccioni M, Li XY, Marsal J, Arenzana-Seisdedos F, Delaunay T, Ebert EC, Moser B, Parker CM: Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol 2000; 10:325.
  • 46
    Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667.
  • 47
    Pillay K, Coutsoudis A, Agadzi-Naqvi AK, Kuhn L, Coovadia HM, Janoff EN: Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183:653.
  • 48
    Farquhar C, VanCott TC, Mbori-Ngacha DA, Horani L, Bosire RK, Kreiss JK, Richardson BA, John-Stewart GC: Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis 2002; 186:1173.
  • 49
    Hirbod T, Nilsson J, Andersson S, Uberti-Foppa C, Ferrari D, Manghi M, Andersson J, Lopalco L, Broliden K: Upregulation of interferon-alpha and RANTES in the cervix of HIV-1-seronegative women with high-risk behavior. J Acquir Immune Defic Syndr 2006; 43:137.
  • 50
    Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, Hershow RC, Chen HY, Landay A: Lactoferrin, secretory leukocyte protease inhibitor and RANTES (regulated on activation, normal T cell expressed and secreted) in the genital tract of sexually high risk, HIV-seronegative women and the effect of coexisting vaginoses. Clin Vaccine Immunol 2007; 14:1102–1107.
  • 51
    Iqbal SM, Ball TB, Ao Z, Maranan L, Rutherford J, Wachihi C, Pak BJ, Podust VN, Yao X, Plummer FA: Trappin-2: discovery of a novel inhibitor of HIV highly elevated in HIV-resistant sex workers. In Proceedings of the XVI International AIDS Conference, Toronto, ON, International AIDS Society, 2006; 2:5.
  • 52
    Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, Ruzzante S, Salvi A, Semplici F, Longhi R, Fusi ML, Tofani N, Biasin M, Villa ML, Mazzotta F, Clerici M: HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997; 3:1250.
  • 53
    Iqbal SM, Ball TB, Kimani J, Kiama P, Thottingal P, Embree JE, Fowke KR, Plummer FA: Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 2005; 192:728.
  • 54
    Trabattoni D, Caputo SL, Maffeis G, Vichi F, Biasin M, Pierotti P, Fasano F, Saresella M, Franchini M, Ferrante P, Mazzotta F, Clerici M: Human alpha defensin in HIV-exposed but uninfected individuals. J Acquir Immune Defic Syndr 2004; 35:455.
  • 55
    Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, MacDonald KS, Ngugi EN, Plummer FA: Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348:1347.
  • 56
    Kaul R, Pettengell C, Sheth PM, Sunderji S, Biringer A, Macdonald K, Walmsley S, Rebbapragada A: The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol 2007; [Epub ahead of print].
  • 57
    Lavreys L, Baeten JM, Martin HL, Jr, Overbaugh J, Mandaliya K, Ndinya-Achola J, Kreiss JK: Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS 2004; 18:695.
  • 58
    Baeten JM, Lavreys L, Overbaugh J: The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis 2007; 45:360.
  • 59
    Keller MJ, Herold BC: Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract. Am J Reprod Immunol 2006; 56:356.
  • 60
    Sewankambo N, Gray RH, Wawer MJ, Paxton L, McNaim D, Wabwire-Mangen F, Serwadda D, Li C, Kiwanuka N, Hillier SL, Rabe L, Gaydos CA, Quinn TC, Konde-Lule J: HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350:546.
  • 61
    Cohen MS: HIV and sexually transmitted diseases: lethal synergy. Top HIV Med 2004; 12:104.
  • 62
    Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, Mahoney CJ, Miller CJ, Claypool LE, Ho DD, Alexander NJ: Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:1084.
  • 63
    Prakash M, Kapembwa MS, Gotch F, Patterson S: Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(+) T cells in the cervical epithelium of healthy women. J Reprod Immunol 2002; 54:117.
  • 64
    Prakash M, Patterson S, Gotch F, Kapembwa MS: Ex vivo analysis of HIV-1 co-receptors at the endocervical mucosa of women using oral contraceptives. BJOG 2004; 111:1468.
  • 65
    Fichorova RN, Tucker LD, Anderson DJ: The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184:418.
  • 66
    Mallardo M, Dragonetti E, Baldassarre F, Ambrosino C, Scala G, Quinto I: An NF-kappaB site in the 5′-untranslated leader region of the human immunodeficiency virus type 1 enhances the viral expression in response to NF-kappaB-activating stimuli. J Biol Chem 1996; 271:20820.
  • 67
    Hedges SR, Barrientes F, Desmond RA, Schwebke JR: Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis 2006; 193:556.
  • 68
    Sturm-Ramirez K, Gaye-Diallo A, Eisen G, Mboup S, Kanki PJ: High levels of tumor necrosis factor-alpha and interleukin-1beta in bacterial vaginosis may increase susceptibility to human immunodeficiency virus. J Infect Dis 2000; 182:467.
  • 69
    Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF: Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004; 71:761.
  • 70
    Valore EV, Wiley DJ, Ganz T: Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun 2006; 74:5693.
  • 71
    Cohn JA, Hashemi FB, Camarca M, Kong F, Xu J, Beckner SK, Kovacs AA, Reichelderfer PS, Spear GT: HIV-inducing factor in cervicovaginal secretions is associated with bacterial vaginosis in HIV-1-infected women. J Acquir Immune Defic Syndr 2005; 39:340.
  • 72
    Hirbod T, Broliden K: Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Intern Med 2007; 262:44.
  • 73
    Lehner T: Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine 2003; 21(Suppl. 2):S68.
  • 74
    Kulkarni PS, Butera ST, Duerr AC: Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003; 5:87.
  • 75
    Reynolds MR, Rakasz E, Skinner PJ, White C, Abel K, Ma ZM, Compton L, Napoe G, Wilson N, Miller CJ, Haase A, Watkins DI: CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol 2005; 79:9228.
  • 76
    Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O’Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, O’Brien SJ: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998; 279:389.
  • 77
    Beyrer C, Artenstein AW, Rugpao S, Stephens H, VanCott TC, Robb ML, Rinkaew M, Birx DL, Khamboonruang C, Zimmerman PA, Nelson KE, Natpratan C: Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. J Infect Dis 1999; 179:59.
  • 78
    MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, Ball TB, Oyugi J, Njagi E, Gaur LK, Brunham RC, Wade J, Luscher MA, Krausa P, Rowland-Jones S, Ngugi E, Bwayo JJ, Plummer FA: Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181:1581.
  • 79
    Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, Stephens HA, Kostrikis LG, Limpakarnjanarat K, Young NL, Qari SH, Lal RB, Chandanayingyong D, McNicholl JM: HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res Hum Retroviruses 2001; 17:719.
  • 80
    Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M, Jr, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O: Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306:485.
  • 81
    Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438:99.
  • 82
    Pusch O, Kalyanaraman R, Tucker LD, Wells JM, Ramratnam B, Boden D: An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS 2006; 20:1917.
  • 83
    Chancey CJ, Khanna KV, Seegers JF, Zhang GW, Hildreth J, Langan A, Markham RB: Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer. J Immunol 2006; 176:5627.
  • 84
    Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI: Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004; 173:515.
  • 85
    Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M: Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 2000; 355:1981.
  • 86
    Cohen CR, Plummer FA, Mugo N, Maclean I, Shen C, Bukusi EA, Irungu E, Sinei S, Bwayo J, Brunham RC: Increased interleukin-10 in the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission? AIDS 1999; 13:327.
  • 87
    Sawada M, Otsuki K, Mitsukawa K, Yakuwa K, Nagatsuka M, Okai T: Cervical inflammatory cytokines and other markers in the cervical mucus of pregnant women with lower genital tract infection. Int J Gynaecol Obstet 2006; 92:117.
  • 88
    Goldenberg RL, Andrews WW, Guerrant RL, Newman M, Mercer B, Iams J, Meis P, Moawad A, Das A, VanDorsten JP, Caritis SN, Thurnau G, Bottoms S, Miodovnik M, McNellis D, Roberts JM: The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 2000; 182:631.
  • 89
    Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, Ball B, Fowke K, Mazzulli T, Plummer FA, Kaul R: Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007; 21:589.
  • 90
    Humphreys TL, Schnizlein-Bick CT, Katz BP, Baldridge LA, Hood AF, Hromas RA, Spinola SM: Evolution of the cutaneous immune response to experimental Haemophilus ducreyi infection and its relevance to HIV-1 acquisition. J Immunol 2002; 169:6316.
  • 91
    Simhan HN, Anderson BL, Krohn MA, Heine RP, Martinez de Tejada B, Landers DV, Hillier SL: Host immune consequences of asymptomatic Trichomonas vaginalis infection in pregnancy. Am J Obstet Gynecol 2007; 196:59e1.
  • 92
    Kuhn L, Trabattoni D, Kankasa C, Semrau K, Kasonde P, Lissoni F, Sinkala M, Ghosh M, Vwalika C, Aldrovandi GM, Thea DM, Clerici M: Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr 2005; 39:138.
  • 93
    Hoffman IF, Taha TE, Padian NS, Kelly CW, Welch JD, Martinson FE, Kumwenda NI, Rosenberg ZF, Chilongozi DA, Brown JM, Chirenje M, Richardson BA: Nonoxynol-9 100 mg gel: multi-site safety study from sub-Saharan Africa. AIDS 2004; 18:2191.
  • 94
    Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, Gross M, Fleming TR, Buchbinder S, Haggitt RC, Levine H, Kelly CW, Celum CL: Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Dis 1999; 26:564.
  • 95
    Kiviat NB, Paavonen JA, Wolner-Hanssen P, Critchlow CW, Stamm WE, Douglas J, Eschenbach DA, Corey LA, Holmes KK: Histopathology of endocervical infection caused by Chlamydia trachomatis, herpes simplex virus, Trichomonas vaginalis, and Neisseria gonorrhoeae. Hum Pathol 1990; 21:831.